Literature DB >> 8617766

Ubiquitinylation of transcription factors c-Jun and c-Fos using reconstituted ubiquitinylating enzymes.

M L Hermida-Matsumoto1, P B Chock, T Curran, D C Yang.   

Abstract

Recombinant c-Jun and c-Fos were ubiquitinylated by the ubiquitin carrier enzymes E214K, E220K, or E232K in the presence of the ubiquitin-activating enzyme, E1. Addition of ubiquitin protein ligase E3 substantially enhanced the E214K-mediated ubiquitinylation of c-Jun and c-Fos. Truncated c-Jun and c-Fos mutant proteins including wbJun and wbFos were also ubiquitinylated under the same conditions, suggesting the sites of ubiquitinylation are located within the dimerization and DNA binding domains of c-Jun and c-Fos. The E3-dependent ubiquitinylation of c-Jun was inhibited upon the heterodimerization of c-Jun with c-Fos. Further addition of E220K significantly enhanced ubiquitinylation of c-Jun in the heterodimer suggesting a regulatory role of E220K. Polyubiquitinylated c-Jun, wbFos, and wbJun, but not E220K-ubiquitinylated c-Jun, were readily degraded by the ATP-dependent 26 S multicatalytic proteases. These results suggest that the temporal control of c-Jun and c-Fos may be regulated through the ubiquitinylation pathways, and the ubiquitinylation of c-Jun and c-Fos may in turn be regulated in response to the heterodimerization between them and the cooperation between E220K and E3 mediated polyubiquitinylation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617766     DOI: 10.1074/jbc.271.9.4930

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo?

Authors:  C Salvat; C Aquaviva; I Jariel-Encontre; P Ferrara; M Pariat; A M Steff; S Carillo; M Piechaczyk
Journal:  Mol Biol Rep       Date:  1999-04       Impact factor: 2.316

Review 2.  Complex mechanisms for c-fos and c-jun degradation.

Authors:  I Jariel-Encontre; C Salvat; A M Steff; M Pariat; C Acquaviva; O Furstoss; M Piechaczyk
Journal:  Mol Biol Rep       Date:  1997-03       Impact factor: 2.316

3.  GnRH increases c-Fos half-life contributing to higher FSHβ induction.

Authors:  Gaddameedi R Reddy; Changchuan Xie; Lacey L Lindaman; Djurdjica Coss
Journal:  Mol Endocrinol       Date:  2012-12-28

Review 4.  The 26S proteasome complex: an attractive target for cancer therapy.

Authors:  Sarah Frankland-Searby; Sukesh R Bhaumik
Journal:  Biochim Biophys Acta       Date:  2011-10-18

5.  Decreased susceptibility to calpains of v-FosFBR but not of v-FosFBJ or v-JunASV17 retroviral proteins compared with their cellular counterparts.

Authors:  A M Steff; S Carillo; M Pariat; M Piechaczyk
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

6.  Nuclear degradation of particular Fos family members expressed following injections of NMDA and kainate in murine hippocampus.

Authors:  Noritaka Nakamichi; Takayuki Manabe; Yukio Yoneda
Journal:  Neurochem Res       Date:  2002-02       Impact factor: 3.996

7.  Effects of sleep on wake-induced c-fos expression.

Authors:  R Basheer; J E Sherin; C B Saper; J I Morgan; R W McCarley; P J Shiromani
Journal:  J Neurosci       Date:  1997-12-15       Impact factor: 6.167

8.  c-Fos proto-oncoprotein is degraded by the proteasome independently of its own ubiquitinylation in vivo.

Authors:  Guillaume Bossis; Patrizia Ferrara; Claire Acquaviva; Isabelle Jariel-Encontre; Marc Piechaczyk
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

Review 9.  The ubiquitin-proteasome pathway in cancer.

Authors:  V Spataro; C Norbury; A L Harris
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.